Table 2.
SOD2, CAT, GPx, TXN, SEPP1, SEP15 and SELS polymorphisms and risk of CKD
| Polymorphism | Genotype | CKD (+) (n = 568) | CKD (–) (n = 2,717) | aOR (95% CI) | Trend p |
|---|---|---|---|---|---|
| SOD2 Val16Pro (T201C) (rs4880) | T/T | 442 (77.8%) | 2,033 (74.8%) | Reference | |
| T/C | 117 (20.6%) | 628 (23.1%) | 0.88 (0.70–1.10) | 0.198 | |
| C/C | 9 (1.6%) | 56 (2.1%) | 0.77 (0.37–1.59) | ||
| CAT C–262T (rs1001179) | C/C | 545 (96.0%) | 2,546 (93.7%) | Reference | |
| C/T | 23 (4.0%) | 168 (6.2%) | 0.67 (0.43–1.06) | 0.070 | |
| T/T | 0 (0.0%) | 3 (0.1%) | 0 (–) | ||
| GPx1 Pro198Leu (rs1050450) | C/C | 489 (86.1%) | 2,332 (85.8%) | Reference | |
| C/T | 73 (12.9%) | 364 (13.4%) | 0.94 (0.72–1.24) | 0.951 | |
| T/T | 6 (1.1%) | 21 (0.8%) | 1.37 (0.54–3.49) | ||
| GPx4 Ex7 + 77C>T (Leu220Leu) (rs713041) | C/C | 247 (43.5%) | 1,140 (42.0%) | Reference | |
| C/T | 253 (44.5%) | 1,217 (44.8%) | 0.97 (0.80–1.19) | 0.340 | |
| T/T | 68 (12.0%) | 360 (13.2%) | 0.85 (0.63–1.14) | ||
| GPx4 273 bp 3' of STP [C>T] (rs2075710) | C/C | 382 (67.3%) | 1,802 (66.3%) | Reference | |
| C/T | 165 (29.0%) | 823 (30.3%) | 0.96 (0.78–1.18) | 0.954 | |
| T/T | 21 (3.7%) | 92 (3.4%) | 1.12 (0.68–1.84) | ||
| TXNRD1 IVS1–181 [C>G] (rs35009941) | C/C | 539 (94.9%) | 2,582 (95.0%) | Reference | |
| C/G | 29 (5.1%) | 132 (4.9%) | 1.17 (0.97–1.41) | 0.879 | |
| G/G | 0 (0.0%) | 3 (0.1%) | 1.02 (0.67–1.56) | ||
| SEPP1 1345G>A (3' UTR) (rs7579) | G/G | 224 (39.4%) | 1,028 (37.8%) | Reference | |
| A/G | 256 (45.1%) | 1,292 (47.6%) | 0.90 (0.73–1.10) | 0.720 | |
| A/A | 88 (15.5%) | 397 (14.6%) | 1.00 (0.76–1.32) | ||
| SEPP1 31,174 bp 3' of STP (rs12055266) | G/G | 242 (42.6%) | 1,138 (41.9%) | Reference | |
| G/A | 245 (43.1%) | 1,253 (46.1%) | 0.90 (0.73–1.10) | 0.745 | |
| A/A | 81 (14.3%) | 326 (12.0%) | 1.00 (0.76–1.32) | ||
| SEPP1 43,881 bp 3' of STP (rs3797310) | G/G | 224 (39.4%) | 1,028 (37.8%) | Reference | |
| A/G | 256 (45.1%) | 1,291 (47.5%) | 0.90 (0.73–1.10) | 0.716 | |
| A/A | 88 (15.5%) | 398 (14.6%) | 1.00 (0.76–1.32) | ||
| SEPP1 44,321 bp of 3' of STP [C>T] (rs2972994) | T/T | 174 (30.6%) | 780 (28.7%) | Reference | |
| C/T | 273 (48.1%) | 1,391 (51.2%) | 0.87 (0.70–1.07) | 0.609 | |
| C/C | 121 (21.3%) | 546 (20.1%) | 0.95 (0.73–1.24) | ||
| SELS G-105A (rs34713741) | G/G | 284 (50.0%) | 1,418 (52.2%) | Reference | |
| A/G | 237 (41.7%) | 1,080 (39.7%) | 1.10 (0.90–1.33) | 0.339 | |
| A/A | 47 (8.3%) | 219 (8.1%) | 1.11 (0.78–1.57) | ||
| SEP15 3'-UTR (rs5859) | G/G | 520 (91.5%) | 2,493 (91.8%) | Reference | |
| G/A | 47 (8.3%) | 217 (8.0%) | 0.99 (0.70–1.38) | 0.900 | |
| A/A | 1 (0.2%) | 7 (0.3%) | 0.85 (0.10–7.07) |
aOR: adjusted odds ratio (adjusted for age and sex); CKD: chronic kidney disease; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; TXNRD, thioredoxin reductase; SEPP, selenoprotein P; SELS, selenoprotein S; SEP15, 15kDa selenoprotein.